Keyphrases
Advanced Hepatocellular Carcinoma
100%
Adverse Events
100%
Adverse Outcomes
14%
Arterial Hypertension
28%
Atezolizumab Plus Bevacizumab
100%
Bleeding
14%
Confidence Interval
100%
Decreased Appetite
28%
Diarrhea
14%
Efficacy Outcomes
14%
First-line Regimen
14%
Germany
14%
Hazard Ratio
100%
Hepatocellular Carcinoma
42%
Immune Checkpoint Inhibitors
14%
Immune-related Adverse Events
14%
Immunotoxicity
14%
Independent Prognostic Factor
28%
Italy
14%
Japan
14%
Multivariate Analysis
14%
Overall Survival
14%
Portugal
14%
Predictive Factors
100%
Predictive Value
14%
Prognostic Value
28%
Progression-free Survival
14%
Proteinuria
28%
South Korea
14%
Systemic Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Adverse Outcome
12%
Atezolizumab
100%
Bevacizumab
100%
Bleeding
12%
Decreased Appetite
25%
Diarrhea
12%
Hypertension
25%
Immune Checkpoint Inhibitor
12%
Immunotoxicity
12%
Liver Cell Carcinoma
100%
Overall Survival
12%
Population Study
12%
Progression Free Survival
12%
Proteinuria
25%